Glancy Prongay & Murray LLP Commences Investigation on Behalf of Genocea Biosciences, Inc. Investors (GNCA)

Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Genocea Biosciences, Inc. (“Genocea” or the “Company”) (NASDAQ: GNCA) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Genocea investigation page on our website at www.glancylaw.com/case/genocea-biosciences-inc.

On September 25, 2017, Genocea disclosed that it was ceasing spending and other activities related to GEN-003, and exploring “strategic alternatives.” Genocea also announced that it was cutting its workforce by 40%.

On this news, Genocea’s share price fell $4.08, or 76.5%, to close at $1.25 on September 26, 2017, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased Genocea securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171128006149/en/

Glancy Prongay & Murray LLP, Los Angeles/New York
Lesley Portnoy, 310-201-9150 or 888-773-9224
[email protected]
www.glancylaw.com